Trial Profile
An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary) ; Enoxaparin sodium
- Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
- Focus Therapeutic Use
- Acronyms OASIS-5
- Sponsors GlaxoSmithKline; GSK
- 10 May 2011 Actual initiation date (Apr 2003) added as reported by ClinicalTrials.gov.
- 10 May 2011 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 10 May 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.